• Aelis Farma kept its plan to complete enrollment of 188 patients in its AEF0217 Phase 2b Down syndrome trial by end-2026.
• Results disclosure targeted for late 2027, subject to enrollment completion and study follow-up staying on schedule.
• Trial to continue unchanged, with the next IDMC safety review planned once at least 40 patients reach 12 weeks of treatment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aelis Farma SA published the original content used to generate this news brief on July 16, 2026, and is solely responsible for the information contained therein.